Homocysteine in relation to cognitive performance in pathological and non-pathological conditions

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 10, 2005, Pages 1089-1095

  Teunissen, Charlotte E ^a   van Boxtel, Martin P J ^b   Jolles, Jellemer ^b   de Vente, Jan ^b   Vreeling, Fred ^c   Verhey, Frans ^c   Polman, Chris H ^a   Dijkstra, Christine D ^a   Blom, Henk J ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Cognition; Dementia; Homocysteine; Multiple sclerosis

Indexed keywords

HOMOCYSTEINE; LEVODOPA; NITRIC OXIDE; VITAMIN B GROUP;

AGING; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; CENTRAL NERVOUS SYSTEM; CLINICAL LABORATORY; COGNITION; COGNITIVE DEFECT; CORRELATION FUNCTION; DATA ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; LEARNING; MEASUREMENT; MENTAL PERFORMANCE; MENTAL TEST; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITION DISORDERS; HOMOCYSTEINE; HUMANS; MULTIPLE SCLEROSIS;

EID: 27744555439     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.190     Document Type: Review

References (56)

1. Regland B, Abrahamsson L, Gottfries CG, Magnus E. Vitamin B12 analogues, homocysteine, methylmalonic acid, and transcobalamins in the study of vitamin B12 deficiency in primary degenerative dementia. Dementia 1990;1:272-7.
2. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-55.
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-83.
4. Budge M, Johnston C, Hogervorst E, de Jager C, Milwain E, Iversen SD, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000;903:407-10.
5. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999;150:283-9.
6. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001;73:927-33.
7. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-13.
8. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-14.
9. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001; 12:309-13.
10. Teunissen CE, Blom AH, van Boxtel MP, Bosma H, de Bruijn C, Jolles J, et al. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging 2003;7:153-9.
11. Jolles J, Houx PJ, van Boxtel MP, Ponds RW. The Maastricht Aging Study. Determinants of cognitive aging. Maastricht: Neuropsych Publishers, 1995.
12. van Boxtel MP, Gaillard C, Houx PJ, Buntinx F, de Leeuw PW, Jolles J. Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction? J Hypertens 1998;16:1425-32.
13. Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005;118:161-7.
14. Chertkow H. Mild cognitive impairment. Curr Opin Neurol 2002;15:401-7.
15. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004;62:1972-6.
16. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004;80:114-22.
17. Ariogul S, Cankurtaran M, Dagli N, Khalil M, Yavuz B. Vitamin B(12), folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr 2005;40: 139-46.
18. O'Suilleabhain P, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004;61: 633-4.
19. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-91.
20. Bleich S, Otto M, Zerr I, Kropp S, Kretzschmar HA, Wiltfang J. Creutzfeldt-Jakob disease and homocysteine levels in plasma and cerebrospinal fluid. Gerontology 2005;51:142-4.
21. Teunissen CE, Lutjohann D, Von Bergmann K, Verhey F, Vreeling F, Wauters A, et al, Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 2003;24:893-902.
22. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004;61:226-30.
23. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004;63:89-93.
24. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-91.
25. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283-8.
26. Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, et al, Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis, J Neurol 2004;251:1208-14.
27. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41.
28. Goodkin DE, Jacobsen DW, Galvez N, Daughtry M, Secic M, Green R. Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol 1994;51:1110-4.
29. Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol 1992;40:225-30.
30. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003; 6:189-96.
31. Vrethem M, Mattsson E, Hebelka H, Leerbeck K, Osterberg A, Landtblom AM, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 2003;9:239-45.
32. Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. Am J Med 2002;113:537-42.
33. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002;23:383-8.
34. Robert K, Vialard F, Thiery E, Toyama K, Sinet PM, Janel N, et al. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem 2003;51:363-71.
35. Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain; influence on methyltransferases and cognitive function. J Neural Transm 2004;111:547-67.
36. Refsum H, Ueland PM, Nygard O, Vollset SE. Homecysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
37. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002;51:285-9.
38. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001;276:46896-904.
39. Reis EA, Zugno Al, Franzon R, Tagliari B, Matte C, Lammers ML, et al. Pretreatment with vitamins E and C prevent the impairment of memory caused by homocysteine administration in rats. Metab Brain Dis 2002; 17:211-7.
40. Wyse AT, Zugno Al, Streck EL, Matte C, Calcagnotto T, Wannmacher CM, et al. Inhibition of Na(+),K(+)-ATPase activity in hippocampus of rats subjected to acute administration of homocysteine is prevented by vitamins E and C treatment. Neurochem Res 2002;27: 1685-9.
41. Kubova H, Folbergrova J, Mares P. Seizures induced by homocysteine in rats during ontogenesis. Epilepsia 1995;36:750-6.
42. Fykse EM, Iversen EG, Fonnum F. Inhibition of L-glutamate uptake into synaptic vesicles. Neurosci Lett 1992;135:125-8.
43. +-ATPase activity in parietal, prefrontal and cingulate cortex of young rats. Int J Dev Neurosci. 2004;22:185-90.
44. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369-74.
45. Chung YH, Hong JJ, Shin CM, Joo KM, Kim MJ, Cha CI. Immunohistochemical study on the distribution of homocysteine in the central nervous system of transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res 2003;967:226-34.
46. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000;106:483-91.
47. Schlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000;153:383-9.
48. Zhang F, Slungaard A, Vercellotti GM, ladecola C. Super oxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 1998;274:R1704-11.
49. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, et al. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem 2005;280:5781-8.
50. Kim WK. S-Nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons. Neurosci Lett 1999;265: 99-102.
51. D'Emilia DM, Lipton SA. Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures. Neurosci Lett 1999;265:103-6.
52. Contestabile A, Monti B, Ciani E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. Curr Med Chem 2003;10:2147-74.
53. O'Brien NC, Charlton B, Cowden WB, Willenborg DO. Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J Immunol 2001;167:5904-12.
54. Keilhoff G, Fansa H, Wolf G. Nitric oxide synthase, an essential factor in peripheral nerve regeneration. Cell Mol Biol (Noisy-le-grand) 2003;49:885-97.
55. Kruman, II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6.
56. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966;18:95-113.